LRRK2 and mature T-cell and NK-cell non-Hodgkin lymphoma: When dasatinib was used in the relapsed/refractory setting, the overall response rate among 10 PTCL patients was approximately 50%; however, 2 patients with PTCL/NOS carrying LRRK2 mutations achieved stable and durable complete remission (56).